Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Post by Dude51on May 09, 2020 7:40am
344 Views
Post# 31006428

Beam me up Scotty

Beam me up Scotty
"KALYTERA ANNOUNCES EXTENSION OF MATURITY DATE OF PROMISSORY NOTE
In connection with the company's previously announced intention to acquire Stero Biotechs Ltd., Kalytera Therapeutics Inc. and the former shareholders of the company's subsidiary, Talent Biotechs Ltd., have agreed to extend the maturity date of the secured promissory note in favour of such shareholders to May 15, 2020, the date by which the company expects to complete the acquisition of Stero." 
 
So the Stero deal is toast but the Promissory Note is stll alive, right?

"The company is working with its auditors and anticipates it will file the filings by June 14, 2020. In the interim, members of the company's management and other insiders are subject to a trading blackout policy that reflects the principles in Section 9 of National Policy 11-207."

This is still a live date, right?

Scotty I unfortunately can find no news for your dates. Please advise?

<< Previous
Bullboard Posts
Next >>